MicroRNA-193b Enhances Tumor Progression via Down Regulation of Neurofibromin 1

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Lenarduzzi, Michelle ^a,b   Hui, Angela B Y ^a   Alajez, Nehad M ^c   Shi, Wei ^a   Williams, Justin ^a   Yue, Shijun ^a   O'Sullivan, Brian ^b,d   Liu, Fei Fei ^a,b,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MICRORNA; MICRORNA 193B; NEUROFIBROMIN; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DRUG MECHANISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; OVERALL SURVIVAL; PREDICTION; TUMOR GROWTH;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICRORNAS; MODELS, BIOLOGICAL; NEUROFIBROMIN 1; PROGNOSIS;

EID: 84872386811     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053765     Document Type: Article

References (54)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Ferlay J SH, Bray F, Forman D, Mathers C, Parkin DM (2008) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10.
3. Leemans CR, Braakhuis BJ, Brakenhoff RH, (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22.
4. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
5. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
6. Ventura A, Jacks T, (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136: 586-591.
7. Croce CM, (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714.
8. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. (2005) RAS is regulated by the let-7 microRNA family. Cell 120: 635-647.
9. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, et al. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801.
10. Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, et al. (2010) Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 16: 1129-1139.
11. Avissar M, Christensen BC, Kelsey KT, Marsit CJ, (2009) MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 15: 2850-2855.
12. Cummings B, Keane T, Pintilie M, Warde P, Waldron J, et al. (2007) Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol 85: 7-16.
13. Pekkola-Heino K, Kulmala J, Grenman R, (1992) Sublethal damage repair in squamous cell carcinoma cell lines. Head Neck 14: 196-199.
14. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, et al. (2007) Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 29: 163-188.
15. Hui AB, Yue S, Shi W, Alajez NM, Ito E, et al. (2009) Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clin Cancer Res 15: 3716-3724.
16. Moniz LS, Stambolic V, (2011) Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response to UV irradiation. Mol Cell Biol 31: 30-42.
17. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, et al. (2011) MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 71: 2381-2391.
18. Le LQ, Parada LF, (2007) Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene 26: 4609-4616.
19. Nakamura T, Gulick J, Pratt R, Robbins J, (2009) Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations. Proc Natl Acad Sci U S A 106: 15436-15441.
20. Worley LA, Long MD, Onken MD, Harbour JW, (2008) Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res 18: 184-190.
21. Unno K, Zhou Y, Zimmerman T, Platanias LC, Wickrema A, (2009) Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma 50: 1865-1871.
22. van Kouwenhove M, Kedde M, Agami R, (2011) MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 11: 644-656.
23. Zhang X, Cairns M, Rose B, O'Brien C, Shannon K, et al. (2009) Alterations in miRNA processing and expression in pleomorphic adenomas of the salivary gland. Int J Cancer 124: 2855-2863.
24. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, et al. (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256.
25. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, et al. (2010) miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 127: 1363-1372.
26. Li XF, Yan PJ, Shao ZM, (2009) Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 28: 3937-3948.
27. Gao XN, Lin J, Gao L, Li YH, Wang LL, et al. (2011) MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. Leuk Res 35: 1226-1232.
28. Fletcher AM, Heaford AC, Trask DK, (2008) Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specific mir-205. Transl Oncol 1: 202-208.
29. Tran N, McLean T, Zhang X, Zhao CJ, Thomson JM, et al. (2007) MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 358: 12-17.
30. Wu W, Lin Z, Zhuang Z, Liang X, (2009) Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev 18: 50-55.
31. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, et al. (2008) Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54: 1696-1704.
32. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, et al. (2007) Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612-11620.
33. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
34. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, et al. (1990) The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63: 843-849.
35. Cancer Genome Atlas Research Network, (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
36. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
37. Li Y, Bollag G, Clark R, Stevens J, Conroy L, et al. (1992) Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell 69: 275-281.
38. The I, Murthy AE, Hannigan GE, Jacoby LB, Menon AG, et al. (1993) Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Genet 3: 62-66.
39. Thiel G, Marczinek K, Neumann R, Witkowski R, Marchuk DA, et al. (1995) Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours. Anticancer Res 15: 2495-2499.
40. Johnson MR, DeClue JE, Felzmann S, Vass WC, Xu G, et al. (1994) Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol Cell Biol 14: 641-645.
41. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, et al. (2011) Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 3: 192-222.
42. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, et al. (2002) Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538-548.
43. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648.
44. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379.
45. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, et al. (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11: 21-28.
46. Cassell A, Grandis JR, (2010) Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs 19: 709-722.
47. Wood PA, Yang X, Hrushesky WJ, (2009) Clock genes and cancer. Integr Cancer Ther 8: 303-308.
48. Hsu CM, Lin SF, Lu CT, Lin PM, Yang MY, (2011) Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumour Biol 33: 149-155.
49. Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, et al. (2005) Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 106: 2827-2836.
50. Fu L, Pelicano H, Liu J, Huang P, Lee C, (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111: 41-50.
51. Wolfer A, Ramaswamy S, (2011) MYC and metastasis. Cancer Res 71: 2034-2037.
52. Boston SR, Deshmukh R, Strome S, Priyakumar UD, MacKerell AD Jr, et al. (2011) Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9. BMC Cancer 11: 7.
53. Ohori M, Kinoshita T, Okubo M, Sato K, Yamazaki A, et al. (2005) Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun 336: 357-363.
54. Hancock CN, Macias A, Lee EK, Yu SY, Mackerell AD Jr, et al. (2005) Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J Med Chem 48: 4586-4595.